Our CEO, Martin Moore, talks to BioPharm international on Meissa's approach to developing an intranasal, recombinant live-attenuated COVID-19 vaccine as a potential global solution.
Meissa is overcoming traditional challenges in attenuating a live virus for use in an intranasal vaccine. “The attenuation of a virus to produce a vaccine must balance reducing its virulence while retaining its ability to stimulate an effective immune response, or immunogenicity,” says Moore.
In Meissa’s case, the development of its intranasal live attenuated recombinant vaccine also carries important opportunities as an end game vaccine for COVID-19.